Form 4: ALX Oncology Director Alan B. Sandler Reports Stock Option Grant

Director Alan B. Sandler reports the acquisition of stock options in ALX Oncology Holdings Inc.

Summary

• On August 5, 2024, Alan B. Sandler, a director of ALX Oncology Holdings Inc., reported a transaction involving derivative securities.
• Sandler acquired stock options (right to buy) for 40,400 shares of common stock at an exercise price of $2.73.
• The options vest in 36 equal monthly installments starting September 5, 2024, and expire on August 4, 2034.
• Following the transaction, Sandler directly owns 40,400 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a stock option grant, a common practice in publicly traded companies.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant could incentivize the director to work towards increasing shareholder value.
• Existing shareholders may experience dilution if the options are exercised.

Key Dates